ArticleJournal of translational medicine2025
Construction and validation of a prognostic nomogram model integrating machine learning-pathomics and clinical features in IDH-wildtype glioblastoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundNovel diagnostic criteria for glioblastoma (GBM) in the 2021 WHO classification emphasize the importance of integrating pathological and molecular features. Pathomics, which involves the extraction of digital pathology data, is gaining significant interest in the field of tumor research. This study aimed to construct and validate a nomogram based on machine-learning pathomics for patients with GBM.
methodsWe extracted pathomic features from hematoxylin and eosin (H&E)-stained images of GBM from the Department of Neurosurgery of Nanfang Hospital (n = 125), Department of Neurosurgery of Zhangzhou Affiliated Hospital of Fujian Medical University (n = 96), and The Cancer Genome Atlas (n = 104) using CellProfiler. We then constructed a machine learning-pathomics risk score (PRS) model using the LASSO (least absolute shrinkage and selection operator)-Cox regression method. Clinical data including sex, age, preoperative Karnofsky performance status (KPS), extent of resection, subventricular zone (SVZ) association, and O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status, were also obtained. Differentially expressed gene analysis, gene ontology analysis, and immunohistochemical staining were utilized to establish a link between PRS and GBM molecules. We subsequently constructed a nomogram model integrating PRS with other independent clinical risk factors and was then validated externally.
resultsTen pathomics features were identified using the PRS model. An association between the PRS, tumor location, and molecular characteristics was observed. Notably, the PRS is related to the extracellular matrix, including type 1 and type 6 collagen. Patients with a low PRS, but not those with a high PRS, significantly benefited from supramaximal resection. Moreover, the combination of the PRS, KPS, extent of resection collectively formed a novel prognostic nomogram model with high accuracy.
conclusionsThis novel prognostic nomogram model integrating machine learning pathomics and clinical features for GBM patients, is available as free online software at https://yaomin.shinyapps.io/GBM_Pathomics_Nomogram_NFH/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.